Systemic sclerosis & Raynaud's
Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents
Authors' conclusion
AHSCT is more effective than both RTX and CIT in prolonging survival and inducing prolonged remission in patients with rapidly progressive dcSSc.
Study context
- Population
- Patients with rapidly progressive diffuse cutaneous systemic sclerosis (dcSSc)matched cases
- Participants
- 35 / 29 / 36
- Exposure
- Autologous haematopoietic stem cell transplantation (AHSCT) vs rituximab (RTX) vs conventional immunosuppressive therapies
- AHSCTn = 35
- RTXn = 29
- Conventional immunosuppressive therapies (CIT)n = 36
- Outcome
- Therapy efficacy: overall survival, mRSS, lung function tests (FVC and DLCO) and revised EUSTAR Activity Index (REAI)
- Follow-up
- 5 years
Methodological detailsmatched cases, 5-year follow-up, Followed up for 5 years with outcome measures assessed every year
- Matched cases
- 5-year follow-up
- Followed up for 5 years with outcome measures assessed every year
Main finding
As reported in the abstract
Overall survival, mRSS, REAI, lung function
- AHSCT significantly more effective than RTX and CIT in prolonging survival, inducing a rapid reduction of modified Rodnan skin score (mRSS) and revised EUSTAR Activity Index (REAI) and maintaining baseline lung function tests for longer
- RTX superior to CIT in reducing REAI, mRSS and in saving lung function
Observational data: associations, not effects.
Original publication
Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents. Arthritis Res Ther. Published 23 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →